// App-Quantinova.ai

1503 : Safety Profile of Ixekizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Integrated Analysis of 18 Clinical Trials

Researchers

Presenter

  • Hideto Kameda

Principal Investigators

  • Proton Rahman

  • Juan Canete

  • Sandra Garces

  • Wen Xu

  • Matthew M. Hufford

  • Bernard Combe

Medical Centers

  • Toho University, Tokyo, Japan, Tokyo, Japan

  • Memorial University, Newfoundland, Canada

  • Department of Pathology, Hospital Clinic de Barcelona, Barcelona, Spain

  • Eli Lilly and Company, Indianapolis, IN

  • Eli Lilly and Company, Indianapolis, IN

  • CHU Montpellier, Montpellier University, Montpellier, France

Locations

  • United States

  • Japan

  • Canada

  • Spain

  • France

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Genetic Disorder

  • Musculoskeletal

  • Autoimmune (AI)

  • Dermatology

  • Infectious Diseases (ID)

  • Gastroenterology (GU)

Disease

  • Inflammatory bowel disease

  • Psoriatic arthritis

  • Psoriasis

  • Inflammatory Arthritis

Biomarkers

  • N/A

Drug/Treatment

  • LY2439821

  • Suloctidil

Outcome

  • N/A

Study Design

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved